U.S. Markets closed

Illumina, Inc. (ILMN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
176.36-4.53 (-2.50%)
At close: 4:00PM EDT

176.36 0.00 (0.00%)
After hours: 4:34PM EDT

People also watch
ALXNREGNBIIBVRTXCELG
  • (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • ILMN is down -4.92% to 168.94
  • Wait, didn't this scam missed earnings and downwardly revised the guidance big time. Oh I forgot we are in the bubble so all that doesn't matter. But wait what will happen to #$%$ stocks like these when bubble finally goes bonker? It may happen starting Monday. Nasdaq wouldn't stop until it has falled 20-30% or more. Some are saying 80% drop, worst ever after 1929 and 2000.
  • With a positive 700 million in equity after taking cash minus debt into account, and over 25 BILLION in stock value, this company could easily take out EXAS which poses an existential threat to the GRAIL initiative. The time to act is now however, soon their 3 Billion market cap will look like peanuts (See news re: UNH endorsement of the Cologuard Test and the non invasive test they've got on the front burner set to replace Lung Biopsy as a diagnostic tool. This could be highly accretive for ILMN and furthermore, I would HATE to see AMGN beat them to the punch and score here.
  • Bought $181, not long ago; today added $176
  • does Illumina buy Exact Science's (exas) or does Thermo Fisher (tmo) buy Exas first?
  • Earnings always scary with this company , feeling better.
  • Hey shorts - you were too clever by half in trying to peddle your fake news contamination story in front of earnings.
    How ya doing?
  • https://www.wired.com/2017/04/geneticists-fear-illuminas-sequencers-may-distort-results/
    The Go-To Gene Sequencing Machine With Very Strange Results
    The Go-To Gene Sequencing Machine With Very Strange Results
    An update to Illumina's gene sequencing technology could have contaminated the results of recent high-sensitivity data produced on the machines.
    www.wired.com />ReplyReplies (2)40

  • http://biorxiv.org/content/early/2017/04/09/125724
    This could be a huge issue for Illumina. It seems to be a problem with all of their new systems that rely upon exAMP.

    Index Switching Causes “Spreading-Of-Signal” Among Multiplexed Samples In Illumina HiSeq 4000 DNA Sequencing | bioRxiv
    bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
    biorxiv.org
  • http://yugestocks.com/?s=ILMN has an alert for $ILMN. Did anyone happen to see it as well? Looking for some good positive information from the company! Making money trading stocks. Miller's law: you can't tell how deep a puddle is until you step into it.

    Yuge Stocks: Trading Stocks and Making Money
    Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
    yugestocks.com
  • Love is like soup. The first mouthful is very hot, http://dataunion.tistory.com/2254

    [2016-MAY] Illumina NASDAQ : ILMN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • ILMN should buy Fitbit.
  • Guy's , just got a look at Chinese firms buying new systems. This quarter will be huge.
  • why is this greedy management not paying dividends with such a strong b/s?
  • Why is this down this morning ?
  • Big news out AH from EXAS: http://www.exactsciences.com/about/latest-news/exact_sciences_and_mayo_clinic_study_shows_promise_of_new_blood_based_lung_cancer_test

    Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test
    A study from Exact Sciences Corp. and Mayo Clinic shows promise for the development of a blood-based lung cancer test.
    www.exactsciences.com
  • Has HGTM just presented a viable threat to ILMN? Or perhaps simply become an acquisition target?